Cloud DX Valuation
Is CDX.H undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CDX.H when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate CDX.H's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate CDX.H's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CDX.H?
Key metric: As CDX.H is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is CDX.H's PS Ratio? | |
|---|---|
| PS Ratio | 6.2x |
| Sales | CA$1.95m |
| Market Cap | CA$12.09m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 15.3x |
| Enterprise Value/EBITDA | -4.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CDX.H's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.8x | ||
KOVO Kovo+ Holdings | 0.5x | n/a | CA$6.0m |
CRBK Carebook Technologies | 0.4x | n/a | CA$6.2m |
TELE Telecure Technologies | 15.9x | n/a | CA$7.6m |
NURS Hydreight Technologies | 2.3x | n/a | CA$25.4m |
CDX.H Cloud DX | 6.2x | n/a | CA$12.1m |
Price-To-Sales vs Peers: CDX.H is expensive based on its Price-To-Sales Ratio (6.2x) compared to the peer average (0.6x).
Price to Sales Ratio vs Industry
How does CDX.H's PS Ratio compare vs other companies in the CA Healthcare Services Industry?
Price-To-Sales vs Industry: CDX.H is expensive based on its Price-To-Sales Ratio (6.2x) compared to the North American Healthcare Services industry average (3x).
Price to Sales Ratio vs Fair Ratio
What is CDX.H's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6.2x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate CDX.H's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
NeuPath Health
CA$9.0m
Provides chronic pain management services in Canada.
NPTH
CA$0.17
7D
6.3%
1Y
9.7%
Medical Facilities
CA$369.6m
Through its subsidiaries, owns and operates specialty hospitals and ambulatory surgery center in the United States.
DR
CA$15.55
7D
3.2%
1Y
79.1%
Carebook Technologies
CA$6.2m
Engages in the development and commercialization of digital health platforms for assessments, reporting, and targeted solutions in Canada, the United States, Europe, Latin America, Asia, and internationally.
CRBK
CA$0.05
7D
-37.5%
1Y
-28.6%